Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.
Nicholas A TurnerAndrew StrandDilraj S GrewalGary CoxSana ArifArthur W BakerEileen K MaziarzJennifer H SaulloCameron R WolfePublished in: Antimicrobial agents and chemotherapy (2019)
Treatment options for drug-resistant cytomegalovirus (CMV) are limited. Letermovir is a novel antiviral recently approved for CMV prophylaxis following hematopoietic cell transplantation, but its efficacy in other settings is unknown. We recently used letermovir for salvage treatment in four solid organ transplant recipients with ganciclovir-resistant CMV retinitis. All patients improved clinically without known adverse drug events. However, three patients failed to maintain virologic suppression, including two patients who developed genotypically confirmed resistance to letermovir while on therapy.
Keyphrases
- drug resistant
- end stage renal disease
- multidrug resistant
- acinetobacter baumannii
- chronic kidney disease
- ejection fraction
- newly diagnosed
- adverse drug
- peritoneal dialysis
- prognostic factors
- emergency department
- epstein barr virus
- stem cells
- pseudomonas aeruginosa
- mesenchymal stem cells
- cystic fibrosis
- hiv infected
- electronic health record
- cell therapy